IL157330A0 - Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors - Google Patents

Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Info

Publication number
IL157330A0
IL157330A0 IL15733002A IL15733002A IL157330A0 IL 157330 A0 IL157330 A0 IL 157330A0 IL 15733002 A IL15733002 A IL 15733002A IL 15733002 A IL15733002 A IL 15733002A IL 157330 A0 IL157330 A0 IL 157330A0
Authority
IL
Israel
Prior art keywords
methods
function
muscle mass
factor receptors
releasing factor
Prior art date
Application number
IL15733002A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of IL157330A0 publication Critical patent/IL157330A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
IL15733002A 2001-03-06 2002-03-06 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors IL157330A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/799,978 US6670140B2 (en) 2001-03-06 2001-03-06 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
PCT/US2002/007476 WO2002069908A2 (fr) 2001-03-06 2002-03-06 Procedes d'identification de composes permettant de reguler la masse ou la fonction musculaire au moyen de recepteurs de la corticoliberine

Publications (1)

Publication Number Publication Date
IL157330A0 true IL157330A0 (en) 2004-02-19

Family

ID=25177205

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15733002A IL157330A0 (en) 2001-03-06 2002-03-06 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Country Status (28)

Country Link
US (3) US6670140B2 (fr)
EP (1) EP1379873B1 (fr)
JP (2) JP4331942B2 (fr)
KR (2) KR100598441B1 (fr)
CN (1) CN100520408C (fr)
AR (1) AR032957A1 (fr)
AT (1) ATE429242T1 (fr)
AU (1) AU2002303121B2 (fr)
BR (1) BR0207881A (fr)
CA (1) CA2439170C (fr)
CZ (1) CZ20032395A3 (fr)
DE (1) DE60232063D1 (fr)
ES (1) ES2325485T3 (fr)
HU (1) HUP0402173A2 (fr)
IL (1) IL157330A0 (fr)
MA (1) MA26990A1 (fr)
MX (1) MXPA03008114A (fr)
MY (1) MY134755A (fr)
NO (1) NO20033936L (fr)
NZ (1) NZ527124A (fr)
PE (1) PE20020993A1 (fr)
PL (1) PL367187A1 (fr)
RU (1) RU2260805C2 (fr)
SA (1) SA02230159B1 (fr)
SK (1) SK12132003A3 (fr)
TW (1) TWI227780B (fr)
WO (1) WO2002069908A2 (fr)
ZA (1) ZA200305642B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100879232B1 (ko) * 2000-08-04 2009-01-20 리서치 디벨럽먼트 파운데이션 우로코르틴 단백질 및 이를 포함하는 약제학적 조성물
US20040049009A1 (en) * 2000-09-22 2004-03-11 Klaus Eckart Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
US7815905B2 (en) * 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
WO2008047241A2 (fr) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Peptides du facteur libérateur de corticotrophine modifiés et leurs utilisations
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
US8173378B2 (en) * 2007-05-23 2012-05-08 Pharmacome Llc Methods of using an alpha-1-adrenergic receptor having altered ligand affinity
US8334101B2 (en) * 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
RU2606763C2 (ru) * 2010-12-23 2017-01-10 Амазентис Са Композиции и способы для усиления или поддержания мышечной деятельности
DK2780368T3 (en) * 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
RU2517259C1 (ru) * 2013-03-06 2014-05-27 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) Способ профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой
JP2015071549A (ja) * 2013-10-02 2015-04-16 株式会社ファンケル アトロジン−１抑制剤
RU2568903C2 (ru) * 2014-04-07 2015-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ оценки анаболического действия лекарственных препаратов
WO2016168613A1 (fr) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
KR20190084055A (ko) * 2016-10-20 2019-07-15 코르텐 인코포레이티드 부적응 스트레스 반응에서 기인한 질환의 치료 방법
CA3092334A1 (fr) 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Procedes de modification de composition corporelle

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415558A (en) * 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
US4533654A (en) * 1982-09-29 1985-08-06 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US4605642A (en) * 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US4594329A (en) * 1984-05-14 1986-06-10 The Salk Institute For Biological Studies CRF analogs
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
DE3703340A1 (de) * 1987-02-04 1988-08-18 Dirck Dr Med Oppermann Pharmazeutische zubereitung zur behandlung der herzinsuffizienz
US4908352A (en) * 1987-09-28 1990-03-13 The Salk Institute For Biological Studies Urotensin peptides
US5109111A (en) * 1988-09-23 1992-04-28 The Salk Institute For Biological Studies CRF antagonists
CA1340964C (fr) * 1988-09-30 2000-04-18 Jean E. F. Rivier Analogues du crf
US5278146A (en) * 1988-09-30 1994-01-11 The Salk Institute For Biological Studies CRF analogs
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
US5493006A (en) * 1993-06-16 1996-02-20 The Salk Institute For Biological Studies Cyclic CRF analogs
US5728545A (en) * 1993-06-18 1998-03-17 The Salk Institute Of Biological Studies Cloning and recombinant production of CRF receptor (S)
US6495343B1 (en) * 1993-06-18 2002-12-17 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
DK0724637T4 (da) * 1994-06-14 2002-09-16 Neurocrine Biosciences Inc Kortikotropinfrigørende faktor2-receptorer
EP0860501A3 (fr) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Récepteurs du facteur 2 libérant la corticotropine
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
JP2002504802A (ja) 1995-06-13 2002-02-12 ザ ソルク インスティテュート フォア バイオロジカル スタディース ウロコルチンペプチド
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
US5888811A (en) * 1996-05-23 1999-03-30 Dupont Pharmaceuticals Company Corticotropin-releasing hormone receptor
WO2000005253A2 (fr) * 1998-07-24 2000-02-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Antagonistes specifiques du recepteur de la corticoliberine de type 2 (crfr2)
KR100879232B1 (ko) * 2000-08-04 2009-01-20 리서치 디벨럽먼트 파운데이션 우로코르틴 단백질 및 이를 포함하는 약제학적 조성물
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Also Published As

Publication number Publication date
JP2009029816A (ja) 2009-02-12
US7063954B2 (en) 2006-06-20
PL367187A1 (en) 2005-02-21
EP1379873A4 (fr) 2006-03-22
TWI227780B (en) 2005-02-11
KR100596991B1 (ko) 2006-07-07
JP4331942B2 (ja) 2009-09-16
ZA200305642B (en) 2004-06-22
CZ20032395A3 (cs) 2004-01-14
NZ527124A (en) 2005-11-25
EP1379873A2 (fr) 2004-01-14
MY134755A (en) 2007-12-31
WO2002069908A2 (fr) 2002-09-12
ES2325485T3 (es) 2009-09-07
AR032957A1 (es) 2003-12-03
AU2002303121B2 (en) 2005-11-10
NO20033936D0 (no) 2003-09-05
EP1379873B1 (fr) 2009-04-22
KR20030086289A (ko) 2003-11-07
HUP0402173A2 (hu) 2005-01-28
BR0207881A (pt) 2005-08-30
PE20020993A1 (es) 2002-12-20
CN1820200A (zh) 2006-08-16
MXPA03008114A (es) 2003-12-12
NO20033936L (no) 2003-11-05
US20030165807A1 (en) 2003-09-04
CA2439170C (fr) 2011-05-10
US20060198842A1 (en) 2006-09-07
RU2003129500A (ru) 2005-03-10
US6670140B2 (en) 2003-12-30
DE60232063D1 (de) 2009-06-04
KR20060029704A (ko) 2006-04-06
US7572768B2 (en) 2009-08-11
CA2439170A1 (fr) 2002-09-12
ATE429242T1 (de) 2009-05-15
CN100520408C (zh) 2009-07-29
US20040101911A1 (en) 2004-05-27
SA02230159B1 (ar) 2007-05-06
MA26990A1 (fr) 2004-12-20
WO2002069908A3 (fr) 2003-03-20
KR100598441B1 (ko) 2006-07-10
RU2260805C2 (ru) 2005-09-20
SK12132003A3 (sk) 2004-05-04
JP2004532394A (ja) 2004-10-21

Similar Documents

Publication Publication Date Title
IL157330A0 (en) Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
AP1916A (en) Purine compounds and use thereof as cannabinoid receptor ligands
IL197774A0 (en) Corticotropin releasing factor 2 receptor agonists
EP1435891A4 (fr) Dispositif de stimulation musculaire
HK1081919A1 (en) File mechanism
EP1592436A4 (fr) Composes fixant les recepteurs p2y sb 2 /sb ou p2y sb 1 /sb
GB2389574B (en) Collator
IL173162A0 (en) Methods for identifying compounds for regulating muscle mass or function using dopamine receptors
IL155062A0 (en) Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
GB0226227D0 (en) Receptors
AU2003231199A8 (en) System for internet usage determination
TW516482U (en) Automatic nail feeding apparatus
ZA200404994B (en) Corticotropin releasing factor 2 receptor agonists
IL158063A0 (en) Crf receptor antagonists
EP1369106A4 (fr) Composition en emulsion
AU2003247721A8 (en) Methods for identifying regulators of muscle mass using amylin receptors
SI1558615T1 (sl) Purinske spojine in uporaba le-teh kot ligandov kanabinoidnega receptorja
GB0207869D0 (en) Karabiner
PL383351A1 (pl) Sposoby identyfikacji związków do regulacji masy lub działania mięśni z wykorzystaniem receptorów dopaminowych
GB0206043D0 (en) Intracellular antibodies
GB0203569D0 (en) Intracellular antibodies
TW557855U (en) File clip set
GB0109400D0 (en) Karabiner
GB0315147D0 (en) Binding partners for the thyrotropin receptor and uses thereof
TW589946U (en) Multi functional carabiner